Relay Medical & Fio Corporation Announce Sale to U.S. Government Agency, USAID, to Deploy Fionet Pandemic Platform
Toronto, Ontario--(Newsfile Corp. - December 8, 2020) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company") and Fio Corporation ("Fio") - together Fionet Rapid Response Group ("FRR") - announce a sales agreement with the U.S. Government, through the U.S. Agency for International Development (USAID), to deploy FRR's Fionet Pandemic Platform to over 100 community-based healthcare sites in Africa.
Under the terms of the engagement, the Fionet Platform will be deployed at over 100 community-based healthcare sites, supporting widespread rapid testing, triage and real-time tracking of infectious disease for a contract value of approximately CAD $330,000. Fionet mobile devices will guide or automate frontline healthcare activity, while continuously capturing and transmitting comprehensive frontline data. Meanwhile, in real time, Fionet Portals enable off-site supervisors to track and direct frontline action, and display real time epidemiological information.
With a budget of nearly $20B/year, USAID is the largest aid agency in the world, and accounts for more than half of all U.S. foreign assistance.
"This engagement supports the extensive available evidence that our platform provides accurate testing, triage, and tracking that can be deployed in the community, rather than being confined to the limitations of overburdened hospitals and centralized labs. This capability is indispensable to the effective management of infectious disease and COVID pandemic control. When properly deployed Fionet can alleviate overburdened centralized facilities so that they can focus on critical care and treatment," said Dr Michael Greenberg, CEO of Fionet Rapid Response Group and CEO of Fio Corporation.
USAID approached Fio when Fionet devices detected malaria positivity testing rates that were substantially different from nearby clinics that didn't use Fionet. Subsequent scientific analysis supported Fionet results. Dr Michael Humes of USAID presented this data to the American Society of Tropical Medicine two weeks ago: "Such a difference has considerable implications for true measures of cases, incidence and treatments."1
"This deployment by the world's foremost agency in combating global health challenges and pandemics continues to validate Fionet's value proposition not only as a solution for today's global pandemic but for a wide range of infectious diseases plaguing communities around the world. This is a very exciting development for Fionet as we continue to apply our technology as a legitimate solution to help save lives around the world," said Yoav Raiter, CEO, Relay Medical Corp.
A recently published medical research paper demonstrated that Fionet's automated accuracy was comparable to expert lab technicians2. Fionet's data capture and distribution capability was proven in a paper published in a technical journal by U.S. Defense Threat Reduction Agency3.
SUBSCRIBE: For more information on Relay or to subscribe to the Company's mail list visit: https://www.relaymedical.com/news.
About Fio Corporation
Fio Corporation, privately held and headquartered in Toronto, developed and markets the world's first integrated guidance & tracking IT platform for decentralized healthcare settings, a new category of solution that raises healthcare quality and lowers healthcare costs. The platform enables average healthcare workers in clinics to deliver a new level of quality-controlled diagnostic testing and case management. Simultaneously, as an automated by-product of its clinical use, the platform captures and provides unprecedented frontline data to remote supervisors and stakeholders, enabling real-time remote tracking, insight distribution, and intervention. Fio operates globally in partnership with local distribution, service, and support organizations and also partners with other companies that license its technologies.
About Relay Medical Corp.
Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.
W. Clark Kent
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
EU Investor Relations
Office. +49 (0) 177 774 2314
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.
1ASTMH Annual Meeting, Page 195, Abstract #703 https://www.astmh.org/getmedia/71a0e5e6-7c06-48a4-ab47-d50c4ec870a2/ASTMH-2020-Abstract-Book.pdf Page 195, Abstract # 703.
2BMC Infectious Diseases, 2020 https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-4932-0.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69690